Evaluation of myocardial injury following repeated internal atrial shocks by monitoring serum cardiac troponin I levels

Chest

Volumn 118, Issue 2, 2000, Pages 342-347

  Boriani, Giuseppe ^a   Biffi, Mauro ^b   Cervi, Vittorio ^b   Bronzetti, Gabriele ^b   Magagnoli, Giorgia ^b   Zannoli, Romano ^b   Branzi, Angelo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Atrial fibrillation; Cardioversion; Myocardial injury; Troponin

Indexed keywords

TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HEART CATHETER; HEART MUSCLE INJURY; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0033902974     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.2.342     Document Type: Article

References (46)

1. 1 Cooper RAS, Alferness CA, Smith WM, et al. Internal cardioversion of atrial fibrillation in sheep. Circulation 1993; 87:1673-1686
2. 2 Ayers GM, Alferness CA, Ilina M, et al. Ventricular proar-rhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation 1994; 89:413-422
3. 3 Murgatroyd FD, Slade AKB, Sopher SM, et al. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995; 25:1347-1353
4. 4 Schmitt C, Alt E, Plewan A, et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996; 28:994-999
5. 5 Levy S, Ricard P, Lau CP, et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997; 29:750-755
6. 6 Levy S, Ricard P, Gueunoun M, et al. Low energy cardioversion of spontaneous atrial fibrillation. Circulation 1997; 96: 253-259
7. 7 Boriani G, Biffi M, Bronzetti G, et al. Efficacy and tolerability in fully conscious patients of transvenous low energy internal atrial cardioversion for atrial fibrillation. Am J Cardiol 1998; 81:241-244
8. 8 Wellens HJJ, Lau CP, Luderitz B, et al. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation 1998; 98:1651-1656
9. 9 Jacobsson L, Odmansson I, Nordlander R. Enzyme release after elective cardioversion. Eur Heart J 1990; 11:749-752
10. 10 Ehsani A, Gordon AE, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol 1976; 37:12-18
11. 11 Doherty PW, McLaughlin PR, Billingham M, et al. Cardiac damage produced by direct current countershock applied to heart. Am J Cardiol 1979; 43:225-228
12. 12 Stabilini R, Agostini A, Berni CG. Serum myoglobin, total CK and MB CK isoenzyme after DC cardioversion and during the early phase of acute myocardial infarction. Acta Cardiol 1980; 5:373-380
13. 13 Neumayr G, Hagn C, Ganzer H, et al. Plasma levels of troponin T after electrical cardioversion of atrial fibrillation and flutter. Am J Cardiol 1997; 80:1367-1369
14. 14 Bonnefoy E, Chevalier P, Kirkorian G, et al. Cardiac troponin I does not increase after cardioversion. Chest 1997; 111:15-18
15. 15 Allan JJ, Feld RD, Russel AA, et al. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052-1056
16. 16 O'Neil PG, Faitelson L, Taylor A, et al. Time course of creatine kinase release after termination of sustained ventricular dysrhythmias. Am Heart J 1991; 122:709-714
17. 17 Georges JL, Spentchian M, Caubel C, et al. Time course of troponin I, myoglobin and cardiac enzyme release after electrical cardioversion. Am J Cardiol 1996; 78:825-827
18. 18 Reiffel YA, McCarthy DM, Leahey EB. Does DC conversion affect isoenzyme recognition of myocardial infarction? Am Heart J 1979; 97:269-275
19. 19 Adams JE III, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88:101-106
20. 20 Hartmann F, Kampann M, Frey N, et al. Biochemical markers in the diagnosis of coronary artery disease. Eur Heart J 1998; 19(suppl)N8-N9
21. 21 Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987; 113:1333-1344
22. 22 Adams JE, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330:670-674
23. 23 Adams JE, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40:1291-1295
24. 24 Etievent JP, Chocron S, Toubin G, et al. Use of cardiac troponin I as a marker of perioperative myocardial ischemia. Ann Thorac Surg 1995; 59:1192-1194
25. 25 Adams JE III, Davila-Roman VG, Bessey PQ, et al. Improved detection of cardiac contusion with cardiac troponin I. Am Heart J 1996; 131:308-312
26. 26 Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiacspecific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335:1342-1349
27. 27 Apple FS, Falahati A, Paulsen PR, et al. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem 1997; 43:11:2047-2051
28. 28 Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108:352S-359S
29. 29 Stratus [package insert]. Cardiac troponin-I fluorometric immunoassay labeling. Miami, FL: Dade International, 1997
30. 30 Apple FS, Maturen AJ, Mullins RE, et al. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999; 45:206-212
31. 31 Feng YI, Chen C, Fallon JT, et al. Comparison of cardiac troponin I, creatinine kinase-MB and myoglobin for detection of acute ischemic myocardial injury in a swine model. Am J Clin Pathol 1998; 110:70-77
32. 32 Katritsis D, Hossein-Nia M, Anastasakis A, et al. Use of troponin T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation. Eur Heart J 1997; 18:1007-1013
33. 33 Jakobsson J, Odmansson I, Nordlander R. Enzyme release after elective cardioversion. Eur Heart J 1990; 11:749-752
34. 34 Pauletto P, Scannapieco G, Compostella L, et al. Myocardial damage after DC countershock: myoglobin and CK-MB radioimmunoassay evaluation. Acta Cardiol 1984; 34:115-120
35. 35 Madrid AH, Del Rey JM, Novo L, et al. Biochemical markers and c-troponin I release after radiofrequency catheter ablation. In: Farrè J, Moro C, eds. Ten years of radiofrequency catheter ablation. Armonk, NY: Futura Publishing, 1998; 31-40
36. 36 Metcalfe MJ, Smith F, Jennings K. Does cardioversion of atrial fibrillation result in myocardial damage? BMJ 1988; 296:1364
37. 37 Krause T, Hohnloser SH, Kasper W, et al. Assessment of acute myocardial necrosis after cardiopulmonary resuscitation and cardioversion by means of combined thallium-201/technetium 99 pyrophosphate tomography. Eur J Nucl Med 1995; 22:1286-1291
38. 38 Taker WA. Defibrillation of the heart: ICDs, AEDs and manual. St. Louis, MO: Mosby, 1994; 46-81
39. 39 Tung L. Electrical injury heart muscle cells. In: Lee RC, Cravalho EG, Burke JF, eds. Electrical trauma: the pathophysiology, manifestations and clinical management. New York, NY: Cambridge University Press, 1992; 361-400
40. 40 Trouton TG, Allen JD, Yong LK, et al. Metabolic changes and mitochondrial dysfunction early following transthoracic countershock in dogs. Pacing Clin Electrophysiol 1989; 12:1827-1834
41. 41 Dunbar DN, Tobler HG, Fetter J, et al. Intracavitary electrode catheter cardioversion of atrial tachyarrhythmias in the dog. J Am Coll Cardiol 1986; 7:1015-1027
42. 42 Kalman JM, Power JM, Chen JM, et al. Importance of electrode design, lead configuration and impedance for successful low energy transcatheter atrial defibrillation in dogs. J Am Coll Cardiol 1993; 22:1199-1206
43. 43 Cooper RAS, Plumb VJ, Epstein AE, et al. Marked reduction in internal atrial defibrillation thresholds with dual-current pathways and sequential shocks in humans. Circulation 1998; 97:2527-2535
44. 44 Boriani G, Biffi M, Sammali A, et al. Transvenous atrial cardioversion: a randomized comparison between catheters with different coil length [abstract] Pacing Clin Electrophysiol 1999; 22:850
45. 45 Lau CP, Lok NS. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol 1997; 20:2442-2452
46. 46 Boriani G, Biffi M, Capucci A, et al. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. J Am Coll Cardiol 1999; 33:333-341